EGFR and cancer: Survivin, a prosurvival factor, promoted the resistance against EGFR-TKIs [18, 19] and decreased survivin expression by inhibiting PI3K-Akt signaling pathway and enhanced the chemosensitivity of cancer stem cells to EGFR-TLIs [19].